Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Development of a Novel Class of Microtubule Destabilizing Agents with Selectivity Against Diffuse Large B-Cell Lymphoma (DLBCL) with B-Cell Receptor (BCR) Activation

Benet Pera Gresely, PhD, Francisco de Asís Balaguer, BS, Mariano Gonzalo Cardenas, PhD, Maria Victoria Revuelta, PhD, Maria Nieves Calvo Vidal, PhD, Rossella Marullo, MD PhD, Nahuel Zamponi, PhD, Ildefonso Ismael Rodriguez Rivera, MD, Yong Ai, PhD, Joseph Fraser Glickman, MSPH, PhD, Isabel Barasoain, PhD, Fernando Díaz, PhD, Ari Melnick, MD, Fengtian Xue, PhD, Leandro Cerchietti, MD

Blood (2017) 130 (Supplement 1): 2546.

https://doi.org/10.1182/blood.V130.Suppl_1.2546.2546

Published: 2017

Journal Articles

Prognosis and Outcomes in MDS-MPN Unclassifiable: Single Institution Experience of a Rare Disorder

Ateefa Chaudhury, MD, Rami S. Komrokji, MD, Najla H. Al Ali, BDS, MSc, Ling Zhang, MD, Pardis Vafaii, MD, Jeffrey E. Lancet, MD

Blood (2015) 126 (23): 1698.

https://doi.org/10.1182/blood.V126.23.1698.1698

Published: 2015

Journal Articles

Prognostic Value of Circulating Myeloblasts in Patients with Myelodysplastic Syndromes (MDS): A Proposal for Incorporation in the Revised International Prognostic Scoring System (R-IPSS)

Rami S Komrokji, MD, Eric Padron, MD, Najla H Al Ali, Jeffrey E Lancet, MD, Jeff Hall, PhD, Brian Kwok, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, PhD, Alan F List, MD

Blood (2014) 124 (21): 4650.

https://doi.org/10.1182/blood.V124.21.4650.4650

Published: 2014

Journal Articles

Improved Prognostic Assessment Of Patients With MDS By IPSS-R and MDS-CI

Margot van Spronsen, Margot van Spronsen, Arjan van de Loosdrecht, Martine ED Chamuleau, MD

Blood (2013) 122 (21): 5207.

https://doi.org/10.1182/blood.V122.21.5207.5207

Published: 2013

Journal Articles

Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.

Asmita Mishra, MD, Jeffrey E Lancet, MD, Najla H Al Ali, Eric Padron, MD, Viet Q. Ho, PharmD, BCOP, Bryan J Little, Javier Pinilla-Ibarz, MD, PhD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2012) 120 (21): 2815.

https://doi.org/10.1182/blood.V120.21.2815.2815

Published: 2012

Journal Articles

Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications.

Asmita Mishra, MD, Najla H Al Ali, Maria Corrales-Yepez, MD, Eric Padron, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, Pharm D, PhD, Mohamed A Kharfan-Dabaja, MD, Javier Pinilla-Ibarz, MD, PhD, Bryan J Little, Jeffrey E Lancet, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2012) 120 (21): 2816.

https://doi.org/10.1182/blood.V120.21.2816.2816

Published: 2012

Journal Articles

The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities

Rami S. Komrokji, MD, Najla H Al Ali, Asmita Mishra, MD, Maria Corrales-Yepez, MD, Eric Padron, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, Pharm D, PhD, Bryan J Little, Javier Pinilla-Ibarz, MD, PhD, Jeffrey E Lancet, MD, Alan F. List, MD

Blood (2012) 120 (21): 3852.

https://doi.org/10.1182/blood.V120.21.3852.3852

Published: 2012

Journal Articles

Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes

Rami S. Komrokji, MD, Maria Corrales-Yepez, MD, Najla H Al Ali, Eric Padron, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, Pharm D, PhD, Javier Pinilla-Ibarz, MD, PhD, Jeffrey E Lancet, MD, Alan F. List, MD

Blood (2012) 120 (21): 3826.

https://doi.org/10.1182/blood.V120.21.3826.3826

Published: 2012

Journal Articles

Obesity Is Poor Prognostic Factor in Lower Risk Myelodysplastic Syndrome

Asmita Mishra, MD, Dana E Rollison, PhD, Najla H Al Ali, M.S, Maria Corrales-Yepez, MD, Pearlie K Epling-Burnette, PhD, Jeffrey E. Lancet, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2011) 118 (21): 5018.

https://doi.org/10.1182/blood.V118.21.5018.5018

Published: 2011

Journal Articles

Impact of Iron Chelation Therapy on Overall Survival and AML Transformation in Lower Risk MDS Patients Treated At the Moffitt Cancer Center

Rami S. Komrokji, MD, Najla H Al Ali, M.S, Eric Padron, MD, Jeffrey E. Lancet, MD, Alan F. List, MD

Blood (2011) 118 (21): 2776.

https://doi.org/10.1182/blood.V118.21.2776.2776

Published: 2011

Journal Articles

Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome

Rami S. Komrokji, MD, Najla H Al Ali, M.S, E Alrawi, MD, Eric Padron, MD, Janelle Perkins, PharmD, Teresa Field, MD, PhD, Jeffrey E. Lancet, MD, Alan F. List, MD

Blood (2011) 118 (21): 1712.

https://doi.org/10.1182/blood.V118.21.1712.1712

Published: 2011

Journal Articles

Poor Outcome of Patients with Myelodysplastic Syndrome (MDS) After Azacitidine Treatment Failure

Karen Lin, MD, Tea Reljic, Ambuj Kumar, MD, MPH, Jeffrey E. Lancet, MD, Alan F. List, Rami S. Komrokji, MD

Blood (2010) 116 (21): 2913.

https://doi.org/10.1182/blood.V116.21.2913.2913

Published: 2010

Journal Articles

Validation of the Newly Proposed MD Anderson Prognostic Risk Model for Patients with Myelodysplastic Syndromes

Maria Corrales-Yepez, Jeffrey E. Lancet, MD, Alan F. List, MD, Mohamed A. Kharfan-Dabaja, MD, Teresa Field, MD, PhD, Eric Padron, MD, Rami S. Komrokji, MD

Blood (2010) 116 (21): 444.

https://doi.org/10.1182/blood.V116.21.444.444

Published: 2010

Journal Articles

Outcome of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Decitabine Failure.

Elias Jabbour, Guillermo Garcia-Manero, Jianqin Shan, Susan O’Brien, Jorge Cortes, MD, Farhad Ravandi, Jean-Pierre J Issa, Hagop M Kantarjian

Blood (2008) 112 (11): 1659.

https://doi.org/10.1182/blood.V112.11.1659.1659

Published: 2008

NARROW

Development of a Novel Class of Microtubule Destabilizing Agents with Selectivity Against Diffuse Large B-Cell Lymphoma (DLBCL) with B-Cell Receptor (BCR) Activation

Prognosis and Outcomes in MDS-MPN Unclassifiable: Single Institution Experience of a Rare Disorder

Prognostic Value of Circulating Myeloblasts in Patients with Myelodysplastic Syndromes (MDS): A Proposal for Incorporation in the Revised International Prognostic Scoring System (R-IPSS)

Improved Prognostic Assessment Of Patients With MDS By IPSS-R and MDS-CI

Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.

Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications.

The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities

Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes

Obesity Is Poor Prognostic Factor in Lower Risk Myelodysplastic Syndrome

Impact of Iron Chelation Therapy on Overall Survival and AML Transformation in Lower Risk MDS Patients Treated At the Moffitt Cancer Center

Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome

Poor Outcome of Patients with Myelodysplastic Syndrome (MDS) After Azacitidine Treatment Failure

Validation of the Newly Proposed MD Anderson Prognostic Risk Model for Patients with Myelodysplastic Syndromes

Outcome of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Decitabine Failure.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only